On April 24, 2020, Cell Metabolism published new research by AFAR expert Nir Barzilai, MD, on why metformin is an attractive gerotherapeutic to translate to human trials, highlighting how its mechanisms can impact the hallmarks of aging and their interconnectivity.
The AFAR-managed TAME Trial, led by Dr. Barzilai, aims to provide proof of concept that the biology of aging can be targeted.
Dr. Barzilai is AFAR’s Scientific Director, a 1994 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, a 2010 Irving S. Wright Award winner, and the Director at the Institute for Aging Research and distinguished Professor at the Albert Einstein College of Medicine.
Read the research, “Benefits of Metformin in Attenuating the Hallmarks of Aging,” here.
Learn more about the TAME Trial here.
